A recent review summarizes what is known about these conditions and suggests future research directions and opportunities.
Novo to buy Catalent: the backlash begins – Pharmaceutical Technology
Share this article Novo Nordisk’s announcement this week of plans to buy the top contract development and manufacturing organization (CDMO) Catalent Inc (Somerset, NJ, US)